 |
PDBsum entry 1j91
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Transferase
|
 |
|
Title:
|
 |
Crystal structure of z. Mays ck2 kinase alpha subunit in complex with the atp-competitive inhibitor 4,5,6,7-tetrabromobenzotriazole
|
|
Structure:
|
 |
Casein kinase ii, alpha chain. Chain: a, b. Synonym: ck ii, ck2-alpha. Engineered: yes
|
|
Source:
|
 |
Zea mays. Organism_taxid: 4577. Expressed in: escherichia coli. Expression_system_taxid: 562
|
|
Resolution:
|
 |
|
2.22Å
|
R-factor:
|
0.205
|
R-free:
|
0.268
|
|
|
Authors:
|
 |
R.Battistutta,E.De Moliner,S.Sarno,G.Zanotti,L.A.Pinna
|
Key ref:
|
 |
R.Battistutta
et al.
(2001).
Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazole.
Protein Sci,
10,
2200-2206.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
23-May-01
|
Release date:
|
29-May-02
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P28523
(CSK2A_MAIZE) -
Casein kinase II subunit alpha from Zea mays
|
|
|
|
Seq: Struc:
|
 |
 |
 |
332 a.a.
327 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.2.7.11.1
- non-specific serine/threonine protein kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
|
1.
|
L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H+
|
|
2.
|
L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H+
|
|
 |
 |
 |
 |
 |
L-seryl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-seryl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
L-threonyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-threonyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Protein Sci
10:2200-2206
(2001)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazole.
|
|
R.Battistutta,
E.De Moliner,
S.Sarno,
G.Zanotti,
L.A.Pinna.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Two novel crystal structures of Zea mays protein kinase CK2alpha catalytic
subunit, one in complex with the specific inhibitor
4,5,6,7-tetrabromobenzotriazole (TBB) and another in the apo-form, were solved
at 2.2 A resolution. These structures were compared with those of the enzyme in
presence of ATP and GTP (the natural cosubstrates) and the inhibitor emodin.
Interaction of TBB with the active site of CK2alpha is mainly due to van der
Waals contacts, with the ligand fitting almost perfectly the cavity. One
nitrogen of the five-membered ring interacts with two charged residues, Glu 81
and Lys 68, in the depth of the cavity, through two water molecules. These are
buried in the active site and are also generally found in the structures of
CK2alpha enzyme analyzed so far, with the exception of the complex with emodin.
In the N-terminal lobe, the position of helix alphaC is particularly well
preserved in all the structures examined; the Gly-rich loop is displaced from
the intermediate position it has in the apo-form and in the presence of the
natural cosubstrates (ATP/GTP) to either an upper (with TBB) or a lower position
(with emodin). The selectivity of TBB for CK2 appears to be mainly dictated by
the reduced size of the active site which in most other protein kinases is too
large for making stable interactions with this inhibitor.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
Figure 3.
Fig. 3. (A) Two clipped views of the active site showing
the inhibitor (as cpk model) fitting the cavity are shown. The
molecular surface of the protein is represented as a white mesh.
Bromine atoms are in red, carbon atoms in green, and nitrogen
atoms in blue. (B) Position of TBB with respect to that of ATP
(cyan) and emodin (green) in the catalytic site is shown from
different points of view. Inhibitor rings lay practically in the
same plane of the purine moiety of the natural cosubstrates
(bottom).
|
 |
|
|
|
| |
The above figure is
reprinted
by permission from the Protein Society:
Protein Sci
(2001,
10,
2200-2206)
copyright 2001.
|
|
| |
Figure was
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
G.Cozza,
A.Bortolato,
and
S.Moro
(2010).
How druggable is protein kinase CK2?
|
| |
Med Res Rev,
30,
419-462.
|
 |
|
|
|
|
 |
N.Zhang,
and
R.Zhong
(2010).
Structural basis for decreased affinity of Emodin binding to Val66-mutated human CK2 alpha as determined by molecular dynamics.
|
| |
J Mol Model,
16,
771-780.
|
 |
|
|
|
|
 |
M.Nojiri,
K.M.Loyet,
V.A.Klenchin,
G.Kabachinski,
and
T.F.Martin
(2009).
CAPS Activity in Priming Vesicle Exocytosis Requires CK2 Phosphorylation.
|
| |
J Biol Chem,
284,
18707-18714.
|
 |
|
|
|
|
 |
T.Nakaniwa,
T.Kinoshita,
Y.Sekiguchi,
T.Tada,
I.Nakanishi,
K.Kitaura,
Y.Suzuki,
H.Ohno,
A.Hirasawa,
and
G.Tsujimoto
(2009).
Structure of human protein kinase CK2 alpha 2 with a potent indazole-derivative inhibitor.
|
| |
Acta Crystallogr Sect F Struct Biol Cryst Commun,
65,
75-79.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
R.Prudent,
V.Moucadel,
M.López-Ramos,
S.Aci,
B.Laudet,
L.Mouawad,
C.Barette,
J.Einhorn,
C.Einhorn,
J.N.Denis,
G.Bisson,
F.Schmidt,
S.Roy,
L.Lafanechere,
J.C.Florent,
and
C.Cochet
(2008).
Expanding the chemical diversity of CK2 inhibitors.
|
| |
Mol Cell Biochem,
316,
71-85.
|
 |
|
|
|
|
 |
Y.Suzuki,
J.Cluzeau,
T.Hara,
A.Hirasawa,
G.Tsujimoto,
S.Oishi,
H.Ohno,
and
N.Fujii
(2008).
Structure-activity relationships of pyrazine-based CK2 inhibitors: synthesis and evaluation of 2,6-disubstituted pyrazines and 4,6-disubstituted pyrimidines.
|
| |
Arch Pharm (Weinheim),
341,
554-561.
|
 |
|
|
|
|
 |
G.Srinivas,
S.Babykutty,
P.P.Sathiadevan,
and
P.Srinivas
(2007).
Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent.
|
| |
Med Res Rev,
27,
591-608.
|
 |
|
|
|
|
 |
M.A.Pagano,
G.Poletto,
G.Di Maira,
G.Cozza,
M.Ruzzene,
S.Sarno,
J.Bain,
M.Elliott,
S.Moro,
G.Zagotto,
F.Meggio,
and
L.A.Pinna
(2007).
Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors.
|
| |
Chembiochem,
8,
129-139.
|
 |
|
|
|
|
 |
M.T.Nogalski,
J.P.Podduturi,
I.B.DeMeritt,
L.E.Milford,
and
A.D.Yurochko
(2007).
The human cytomegalovirus virion possesses an activated casein kinase II that allows for the rapid phosphorylation of the inhibitor of NF-kappaB, IkappaBalpha.
|
| |
J Virol,
81,
5305-5314.
|
 |
|
|
|
|
 |
R.Battistutta,
M.Mazzorana,
L.Cendron,
A.Bortolato,
S.Sarno,
Z.Kazimierczuk,
G.Zanotti,
S.Moro,
and
L.A.Pinna
(2007).
The ATP-binding site of protein kinase CK2 holds a positive electrostatic area and conserved water molecules.
|
| |
Chembiochem,
8,
1804-1809.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
C.Y.Lin,
S.Navarro,
S.Reddy,
and
L.Comai
(2006).
CK2-mediated stimulation of Pol I transcription by stabilization of UBF-SL1 interaction.
|
| |
Nucleic Acids Res,
34,
4752-4766.
|
 |
|
|
|
|
 |
R.Battistutta,
M.Mazzorana,
S.Sarno,
Z.Kazimierczuk,
G.Zanotti,
and
L.A.Pinna
(2005).
Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole.
|
| |
Chem Biol,
12,
1211-1219.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.Sarno,
M.Ruzzene,
P.Frascella,
M.A.Pagano,
F.Meggio,
A.Zambon,
M.Mazzorana,
G.Di Maira,
V.Lucchini,
and
L.A.Pinna
(2005).
Development and exploitation of CK2 inhibitors.
|
| |
Mol Cell Biochem,
274,
69-76.
|
 |
|
|
|
|
 |
A.V.Ljubimov,
S.Caballero,
A.M.Aoki,
L.A.Pinna,
M.B.Grant,
and
R.Castellon
(2004).
Involvement of protein kinase CK2 in angiogenesis and retinal neovascularization.
|
| |
Invest Ophthalmol Vis Sci,
45,
4583-4591.
|
 |
|
|
|
|
 |
E.I.Schwartz,
R.V.Intine,
and
R.J.Maraia
(2004).
CK2 is responsible for phosphorylation of human La protein serine-366 and can modulate rpL37 5'-terminal oligopyrimidine mRNA metabolism.
|
| |
Mol Cell Biol,
24,
9580-9591.
|
 |
|
|
|
|
 |
E.Pechkova,
and
C.Nicolini
(2004).
Atomic structure of a CK2alpha human kinase by microfocus diffraction of extra-small microcrystals grown with nanobiofilm template.
|
| |
J Cell Biochem,
91,
1010-1020.
|
 |
|
|
|
|
 |
J.I.Loizou,
S.F.El-Khamisy,
A.Zlatanou,
D.J.Moore,
D.W.Chan,
J.Qin,
S.Sarno,
F.Meggio,
L.A.Pinna,
and
K.W.Caldecott
(2004).
The protein kinase CK2 facilitates repair of chromosomal DNA single-strand breaks.
|
| |
Cell,
117,
17-28.
|
 |
|
|
|
|
 |
E.De Moliner,
N.R.Brown,
and
L.N.Johnson
(2003).
Alternative binding modes of an inhibitor to two different kinases.
|
| |
Eur J Biochem,
270,
3174-3181.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
P.Borowski,
J.Deinert,
S.Schalinski,
M.Bretner,
K.Ginalski,
T.Kulikowski,
and
D.Shugar
(2003).
Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses.
|
| |
Eur J Biochem,
270,
1645-1653.
|
 |
|
|
|
|
 |
S.Sarno,
S.Moro,
F.Meggio,
G.Zagotto,
D.Dal Ben,
P.Ghisellini,
R.Battistutta,
G.Zanotti,
and
L.A.Pinna
(2002).
Toward the rational design of protein kinase casein kinase-2 inhibitors.
|
| |
Pharmacol Ther,
93,
159-168.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |